Back

Pathophysiological impact of one year of tafamidis in patients with transthyretin cardiac amyloidosis

30 August 2026 (14:15 - 14:45)
Organised by: Logo
Congress Presentation Part of: Inherited cardiomyopathies and amyloidosis Cardiomyopathies ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Daiki Yamashita

Mie University Graduate School of Medicine, Tsu (Japan)

4 More presentations in this session

Presentation thumbnail
SUN1 accumulation as a mechanism of impaired mechanotransduction in human lamin a/c cardiomyopathy
Doctor P. Ernst (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
In vivo proximity labeling reveals altered protein networks in PLN-R14del cardiomyopathy
Mr R. Li (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Early mavacamten therapy prevents progression to end-stage hypertrophic cardiomyopathy in a MYBPC3 truncation mouse model
Doctor R. Abe (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Non-dilated left ventricular cardiomyopathy carries distinct circulating epigenetic signatures
Mr B. Hingst (DE)
Abstract Slides Video

Access the full session

Session thumbnail
Inherited cardiomyopathies and amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
A biopsy-based pilot clinical study: monitoring the effectiveness of tafamidis treatment of patients with transthyretin amyloid cardiomyopathy.
25 August 2023
thumbnail
Congress Presentation
Do tafamidis and acoramidis improve survival and cardiovascular outcomes in transthyretin amyloid cardiomyopathy? a systematic review and meta-analysis
30 August 2026
thumbnail
Congress Presentation
A novel 3D in vitro model of cardiac transthyretin amyloidosis to investigate amyloid kinetics
28 August 2026
thumbnail
Congress Presentation
Extracellular volume from cardiac magnetic resonance reflects histologically quantified myocardial amyloid load: stereological validation in transthyretin amyloidosis
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources